	chimeric antibody technology	10.58015898460919
	specifically chimeric antibody	10.573288568535148
	administer antibody	10.055226830066145
	multiple antibody	10.044844008506749
	chimeric humanized antibody	9.531907678633996
	one monoclonal antibody	9.423995063342277
	thirteen murine antibody	8.350722176853944
	Hogan	7.077459192986361
¡°	six additional monoclonal antibody	7.070438028431779
	term monoclonal antibody	7.068010040061157
	genetically engineer antibody	6.996648262547201
	seven antibody	6.702184634855211
	antibody composition	6.697798303858917
	six additional murine antibody	6.207001596480625
	antibody dependent cellular cytoxicity	5.194660096581602
	homogeneous antibody population	5.1726874115102355
¡°	HER2 antigen	4.230717939742019
	one correspond antibody	4.018766139583345
¡°	HER2)-an antigen	4.000127807144115
	hybridoma technology	3.818557224886308
	one antigen	3.705967569629461
	predecessor corporation	3.5584921140839603
	Herceptin	2.937521071624169
	correspond hybridoma	2.5405760525666836
	three additional hybridoma	2.5390024378658986
	hybridoma method	2.5389002618385415
	target antigen	2.49361231378755
	specific antigen	2.470780983197622
	particular antigen	2.4706535240134593
	specific human breast cancer antigen	2.361045312353975
	Plant Genetic Sys	2.014198632480424
	nascent technology	1.7722344813442727
	human c erbb-2 antigen	1.7323092558892927
	approximate antigen molecular weight	1.5165675857867356
	breast cancer cell	1.4934080413008652
	cdr	1.1762322547389803
	Chimeric	1.1762322547389803
	nonhuman portion	0.8819743456612277
	hama response	0.783810497302131
	least three different epitope	0.7047753763984714
	CDR	0.5883204762836581
	hamster	0.5883204762836581
	herceptin	0.5883204762836581
	ethic	0.5883204762836581
	Hyatt	0.5882042976420886
	HAMA	0.5881161273694901
	deposit	0.38010867064252596
	nonexistent technology	0.3495735527260528
	Cetus Corp.	0.29416023949500125
	Bred	0.29416023814182907
	cancerous cell	0.24718697711984589
	diagnosis	0.23656418529328022
	kearn	0.23656418529328022
	wand	0.23392706959396678
	deleterious immunogenic response	0.20637104168581116
	mouse cell	0.2032226214575758
	investigational work	0.19641408499568477
	J.E.M. AG Supply	0.1798381520388572
	diagnostic	0.17927179323981493
	Wands	0.17927179323981493
	Sollac	0.17927179323981493
	Pioneer	0.17927179323981493
	interact	0.16767827122238363
	secondary human immune response	0.15984005652952346
	human immune system	0.15950297121121332
	genetic engineering	0.15700405371272327
	undue experimentation	0.15613893925798786
	impropriety	0.14255475830244016
	dna encode region	0.141800374960073
	clone cell line	0.12656256153515008
	Richfield Co.	0.11828209292188355
	another CIP application	0.11704618161122317
	knowledge continuum	0.1135694283904584
	actual originator	0.11348028158971106
	Monoclonal Antibodies	0.11191953879194248
	scientist	0.10826453657908684
	routine experimentation	0.10512456864672495
	variable region	0.10236959254586371
	enablement requirement	0.10164475747203491
	recombinant dna technique	0.10143328593231775
	accurate accounting	0.09704624612883506
	Y shape protein	0.09474156234642131
	argument	0.08147790281388294
	important academic topic	0.07756903885136976
	primarily two region	0.07408918552985343
	Atl	0.07256651269566955
	complementary determine region	0.07235594813978129
	enablement inquiry	0.06777429474450111
	completely human constant region	0.0656886633978148
	possession	0.06213502990007101
	toxic shock	0.06116428660653829
	Guardian Indus	0.059201055412818414
	even death	0.05850420290415436
	adversary	0.058502087680678064
	Analog Devices	0.05814961850954247
	lexis	0.055988926926172015
	Chrysler Corp.	0.049111908236114755
	jury enablement verdict	0.048198882476176874
	priority date	0.04388057334784283
	modern understanding	0.043217887837484946
	thirteen day jury trial	0.04135072382744799
	Hybritech Inc.	0.04000872078890095
	PPG Indus	0.03946737027521228
	pendency	0.036283256347834775
	Michigan	0.036161031470687596
	N.V.	0.03613828976814628
	numerous bind site	0.03572772756998104
	No. Civ	0.03279692629022763
	successful creation	0.03175726380801557
	priority application	0.028737059827832253
	speculative testimony	0.028016883674371017
	people	0.02729675788043992
	specific bind site	0.026221206805045263
	Hoechst Marion Roussel Inc.	0.025364175783050797
	synthetic portion	0.02498742451730363
	four amino acid chain	0.02365453712597954
	simplify model	0.02217094598895682
	herein	0.019199934856893298
	title	0.019199934856893298
	jury verdict	0.0190892303111436
	gap	0.01807542325319986
	patentee instruction	0.016609223741204545
	Union Oil Co.	0.016451513594085757
	Rader	0.015549945972702452
	various specie	0.015441957664849489
	Wright	0.011579783530556706
	JMOL motion	0.011287160786017872
	California	0.00986971943294899
	Amgen Inc.	0.009770637714959615
	every possible variant	0.009507682842180962
	reasonable clarity	0.009042939640984259
	hypothetical possibility	0.009013412199851372
	short term therapy	0.00890895348060383
	successful technology	0.008789830478095888
	event	0.008487543000690084
	first paragraph	0.008325582114212113
	verdict form	0.008309846306297509
	CCPA	0.007835684516740968
	initial publication	0.00700217457913909
	full enable disclosure	0.006843756064539212
	first publication	0.005978512427605832
	definition	0.005584214331928737
	patient	0.0052274194107693895
	ordinarily skilled artisan	0.005208601467344635
	exact term	0.0048291372696487225
	S.A.	0.004664306288045821
	office	0.004184440494315131
	February filing date	0.0038479594107332553
	artisan knowledge	0.003508338047433196
	advance knowledge	0.002886460067611646
	partial summary judgment	0.002669472557246664
	jury factual finding	0.0026610178451469003
	original filing date	0.0024415945140677077
	name	0.002293054550640966
	deference	0.0022737321953380306
	following disclosure	0.0022087947858077856
	May	0.0019770467862385015
	post trial motion	0.0019734352910192746
	Eastern District	0.0019014167029310167
	specific useful teaching	0.0018973230460534987
	June	0.0016067493444343113
	additional benefit	0.0015630164596790617
	early application	0.001536166730691798
	specific mention	0.0013177173886735616
	important role	0.001283874831528388
	underlying factual finding	0.0012476220440023381
	document	0.001124707025750931
	degree	0.0010820388491481932
	information	0.0010735212001537866
	write description requirement	0.001011647048579296
	long term treatment	0.0009334439912328468
	district court denial	0.0009213464328693578
	applicant	0.0008896662255091925
	October	0.0008870853686947783
	alternative ground	0.0008827852011930429
	little knowledge	0.0007845078377212588
	function	0.0007275032966417311
	January	0.0006276665094773562
	owner	0.0006250689154047811
	September	0.0005973843889327129
	art field	0.000470383794143164
	full scope	0.00046257908624563717
	cross appeal	0.0004432348822468697
	first instance	0.00044048539032436003
	sale	0.00038208444460607503
	citation	0.00035617210453001223
	public end	0.00035515796216167763
	section	0.000331341282366446
	substantial evidence	0.00030751272976930566
	another method	0.0002911159765429674
	amendment process	0.0002785674277191969
	disclose embodiment	0.00027487731244920185
	valid clear convincing evidence	0.0002742637578558499
	consideration	0.00025315139589833225
	specifically independent	0.00024147973316780566
	two requirement	0.0002368054788787319
	legal component	0.00023470642719093527
	various method	0.00020088272914871265
	construction issue	0.0001762484890257467
	particular requirement	0.0001663324070930908
	turn	0.00013370356008167035
	different structure	0.00012620378955660507
	one method	0.00012578916142644855
	good reason	0.00011078810476488498
	invalidity	8.961897764661813e-05
	matter support	8.386136274748707e-05
	example	7.468220494375286e-05
	single type	6.783061295955885e-05
	underlie fact	6.493743381527424e-05
	effect	5.650494877545399e-05
	background	5.644866896084133e-05
	district court construction	5.035861596920699e-05
	neither party	4.737480560549614e-05
	ordinary skill	4.6362541223513774e-05
	opinion	3.088529984515315e-05
	one type	3.0144336542256497e-05
	clear error	2.9670697300141018e-05
	legal conclusion	2.821121770419213e-05
	specification	2.8164155085979564e-05
	jurisdiction	2.3939994068044154e-05
	prior application	1.954719994699215e-05
	Int'l	1.668982861958141e-05
	favor	1.6029801601710887e-05
	inventor	1.5091365675719499e-05
	trial record	1.3800620689337064e-05
	first application	1.3145964681641002e-05
	trial court	1.2946377283654126e-05
	subject matter	3.8167690477897325e-06
	two light	9.927964917047921e-07
	record show	8.594582200142081e-07
	assert	6.156648421966143e-07
	law	2.0281014230050832e-07
	invention	7.027413842684214e-09
	prior art	4.0067676417654e-12
	Court	0.0
	Appeals	0.0
	Fed	0.0
	United States	0.0
